Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.67 |
| ▸ | DRD2 | P14416 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351216 | 0.87 | DRD4 (0.69) | DRD4DRD2MAPTHTTLMNA | |
| SCHEMBL6353709 | 0.81 | DRD4 (0.74) | DRD4DRD2MAPTHTTLMNA | |
| SCHEMBL6354032 | 0.81 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6352967 | 0.81 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6352971 | 0.81 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6352013 | 0.81 | HTR1A (0.62) | DRD4DRD2HTTLMNAKDM4E | |
| SCHEMBL6351426 | 0.79 | HTR1A (0.81) | DRD4DRD2LMNASMN1; SMN2ADORA1 | |
| SCHEMBL6346697 | 0.78 | ADORA1 (0.56) | DRD4DRD2KDM4EALDH1A1ADORA1 | |
| SCHEMBL11829798 | 0.77 | DRD2 (0.66) | DRD4DRD2LMNASMN1; SMN2HTR1A | |
| SCHEMBL7291269 | 0.75 | LMNA (0.67) | MAPTHTTLMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885MAPT 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.